Le Lézard
Classified in: Health
Subject: FDA

At Vance Thompson Vision, New Dry Eye FDA Approval Leads Where No One Expected. Up Your Nose.


SIOUX FALLS, S.D., April 27, 2017 /PRNewswire/ -- Allergan recently announced that it has received FDA approval for TrueTeartm Intranasal Tear Neurostimulator, the first and only FDA-cleared device developed to temporarily increase tear production in adult patients.

"The FDA approval of the TrueTeartm brings new hope to patients suffering from dry eye," says Dr. Vance Thompson. "With the approval, we can now offer our patients an unprecedented solution for their dry eye. We are super excited about this technology."

When it comes to comfortable vision, there is nothing better than your own tears. TrueTeartm helps you create more tears so your DryEye syndrome can heal naturally.

Vance Thompson Vision was one of the first US research sites for this device. TrueTeartm helps stimulate production of multiple layers of the tear film.

"This represents a breakthrough in dry eye as the TrueTeartm delivers a non-invasive and drug free way to increase tear production," says Dr. Alison Tendler. "We are excited to be able to offer new innovations to our patients." 

TrueTeartm is the first of its kind to provide a temporary increase in tear production during neurostimulation. The new advancement is an addition to Allergan's current eye care portfolio. Last May, Allergan announced positive results from two pivotal trials for TrueTeartm that showed an increase in tear production upon nasal neurostimulation in adults with aqueous tear deficiency. 

"We are proud to have performed the very first cases in these studies," says Dr. John Berdahl. "This is further evidence that people who suffer from dry eye really look forward to solutions like these."

About VTV:
At Vance Thompson Vision, we know how important it is to wake up each morning to clear vision. Because improved sight means more than seeing your best. It means being your best. With more than 80,000 procedures and nearly 100 years of combined experience in eye care and refractive surgery, the team at Vance Thompson Vision is committed to using only the most advanced technology and sets standards used all over the globe for vision correction. For more information, visit www.vancethompsonvision.com.

Contact:
Matt Jensen
CEO: Sioux Falls, SD
(605) 371-7120 / [email protected]

 

SOURCE Vance Thompson Vision


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: